Method of Preventing Neurodevelopmental Damage Due to Prenatal Exposure to Environmental Toxins
A method of assessing the risk in female patients of having neurocognitive developmentally disabled children. The method including measuring the toxin concentrations in the urine of a female subject wishing to become pregnant, or of a subject that is pregnant. Quantify the risk of neurocognitive developmentally disabled children born to the subject by comparing the toxin concentrations in the subject to reference concentrations utilizing a weighting algorithm. Advise the patient of the quantified risk of having neurocognitive developmentally disabled children. The concentrations of dialkyl phosphates, endocrine disruptors, and xenoestrogens compounds are evaluated. Additionally, the level of PON1 activity may be included in the risk assessment weighting algorithm.
1 . A method of assessing the risk of a female subject having neurocognitive developmentally disabled children, the method comprising the steps of;
measuring organophosphate concentrations in the urine of a female subject wishing to become pregnant, or of a subject that is pregnant;
determine if the subject has a deficiency of PON1 activity by assessing the presence of a defective PON1 gene by single nucleotide polymorphism (SNP) detection; and
quantify the risk of neurocognitive developmentally disabled children born to the subject by at least one of; comparing the organophosphate concentration in the subject to a reference concentration, by the level of PON1 activity.
2 . The method of claim 1 , the method further comprising the steps of;
determining effective amounts of nutritional supplementation that may reduce the subject's organophosphate concentration towards the reference concentration;
formulating a customized nutritional supplement containing the effective amount of nutritional supplementation; and
administering the nutritional supplementation to the subject over a period of time.
3 . The method of claim 2 , wherein the effective amount of nutritional supplementation is affected by the level of PON1 activity.
4 . The method of claim 2 , further comprising the step of:
quantifying the risk of neurocognitive developmentally disabled children born to the subject subsequent to the nutritional supplementation.
5 . A method of assessing the risk of a female subject having neurocognitive developmentally disabled children, the method comprising the steps of;
measuring toxin concentrations in the urine of a female subject wishing to become pregnant, or of a subject that is pregnant;
determine if the subject has a deficiency of PON1 activity by assessing the presence of a defective PON1 gene by single nucleotide polymorphism (SNP) detection; and
quantify the risk of neurocognitive developmentally disabled children born to the subject by at least one of; comparing the toxin concentrations in the subject to reference concentrations, by the level of PON1 activity.
6 . The method of claim 5 , wherein the toxin concentration measured includes at least one of: Dimethylphosphate (DMP), Dimethylthiophosphate (DMTP), Dimethyldithiophosphate (DMDTP), Diethylphosphate (DEP), Diethylthiophosphate (DETP), and Diethyldithiophosphate (DEDTP)3
7 . The method of claim 5 , wherein the toxin concentration measured includes at least one of: Bisphenol A, Triclosan, and 4-Nonylphenol.
8 . The method of claim 5 , wherein the toxin concentration measured includes at least one of: mono-ethyl phthalate (MEtP),mono-2-ethylhexyl phthalate (MEHP), mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP), methylparaben, ethylparaben, propylparaben, and butylparaben.
9 . The method of claim 5 , the method further comprising the steps of;
determining effective amounts of nutritional supplementation that may reduce the subject's toxin concentrations towards the reference concentrations;
formulating a customized nutritional supplement containing the effective amounts of nutritional supplementation; and
administering the nutritional supplementation to the subject over a period of time.
10 . The method of claim 9 , wherein the effective amount of nutritional supplementation is affected by the level of PON1 activity.
11 . The method of claim 9 , further comprising the step of:
quantify the risk of neurocognitive developmentally disabled children born to the subject subsequent to the nutritional supplementation.
12 . A method of assessing the risk of a female subject having neurocognitive developmentally disabled children, the method comprising the steps of;
measuring toxin concentrations in the urine of a female subject wishing to become pregnant, or of a subject that is pregnant; and
quantify the risk of neurocognitive developmentally disabled children born to the subject by comparing the toxin concentrations in the subject to reference concentrations utilizing a weighting algorithm.
13 . The method of claim 12 , wherein the toxin concentration measured includes at least one of: Dimethylphosphate (DMP), Dimethylthiophosphate (DMTP), Dimethyldithiophosphate (DMDTP), Diethylphosphate (DEP), Diethylthiophosphate (DETP), and Diethyldithiophosphate (DEDTP)3
14 . The method of claim 12 , wherein the toxin concentration measured includes at least one of: Bisphenol A, Triclosan, and 4-Nonylphenol.
15 . The method of claim 12 , wherein the toxin concentration measured includes at least one of: mono-ethyl phthalate (MEtP),mono-2-ethylhexyl phthalate (MEHP), mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP), methylparaben, ethylparaben, propylparaben, and butylparaben.
16 . The method of claim 12 , the method further comprising the steps of;
determining if the subject has a deficiency of PON1 activity by assessing the presence of a defective PON1 gene;
utilizing the PON1 activity level in the weighting algorithm during the quantification of risk of neurocognitive developmentally disabled children.
17 . The method of claim 12 , the method further comprising the steps of;
determining effective amounts of nutritional supplementation that may reduce the subject's toxin concentrations towards the reference concentrations;
formulating a customized nutritional supplement containing the effective amounts of nutritional supplementation; and
administering the nutritional supplementation to the subject over a period of time.
18 . The method of claim 17 , the method further comprising the steps of;
determining if the subject has a deficiency of PON1 activity by assessing the presence of a defective PON1 gene;
wherein the determination of the effective amount of nutritional supplementation is affected by the level of PON1 activity.
19 . The method of claim 17 , further comprising the step of:
quantify the risk of neurocognitive developmentally disabled children born to the subject subsequent to the nutritional supplementation.